This article was originally published in Start Up
Executive SummaryThe founders of NormOxys are working to commercialize molecules similar to those that give migratory birds the fortitude to fly thousands of miles. When the compound inositol pentaphosphate binds to the protein hemoglobin, its presence helps release up to three of the four oxygen molecules that hemoglobin picks up in the lungs and carries out to the body. NormOxys is betting that its lead candidate can help elevate oxygen levels in human tissues that lack it, and so become a treatment for a range of disorders, from heart failure to diabetic retinopathy, traumatic blood loss, and even cancer.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.